BIOCRYST PHARMACEUTICALS INC (BCRX)       10.58  -0.2 (-1.86%)

10.58  -0.2 (-1.86%)

US09058V1035 - Common Stock - After market: 10.74 +0.16 (+1.51%)

BIOCRYST PHARMACEUTICALS INC10.58

NASDAQ:BCRX (1/27/2023, 7:00:00 PM)-0.2 (-1.86%)

After market: 10.74 +0.16 (+1.51%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-21 2023-02-21
Ins Owners 1.42% Inst Owners 79.54%
Market Cap 1.97B Shares 186.42M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 74.44
IPO 03-04 1994-03-04

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BCRX Daily chart

Company Profile

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

Company Info

BIOCRYST PHARMACEUTICALS INC

4505 Emperor Blvd Ste 200

Durham NORTH CAROLINA 27703

P: 19198591302.0

CEO: Jon P. Stonehouse

Employees: 358

Website: https://www.biocryst.com/

BCRX News

News Image3 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first...

News Image6 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...

News Image20 days ago - Seeking AlphaBCRX stock drops as sales for hereditary angioedema therapy lag forecasts (NASDAQ:BCRX)

BioCryst Pharmaceuticals (BCRX) fell ~12% on Monday after announcing lower-than-expected sales for the company's hereditary angioedema therapy Orladeyo. Read the full story here.

News Image20 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in...

News Image20 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH...

News Image24 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

BCRX Twits

Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example